Neutralizing antibodies (NAbs) are soluble proteins secreted by B lymphocytes that specifically recognize surface antigens of pathogens such as viruses or bacteria. By blocking the interaction betweenapathogen anditshost cell receptor,NAbs prevent pathogen entry andsubsequent replication. NAbs are a key indicator for evaluating vaccine efficacy and immune response. Commonly usedmethods for detecting NAbs include live virus neutralization assays, ELISA-based neutralization assays, and pseudovirion-based neutralization assays (PBNA).
● Live virus neutralization assay:
This method uses live viruses to closely mimic the natural infection process, directly assessing an antibody’s ability toinhibit viral entry into host cells. However, due to the infectious and pathogenic nature of liveviruses,these assays require high-level biosafety containment (BSL-3) for handling highly pathogenic viruses.
● ELISA-based neutralization assay:
This method eliminates the need for cell culture, offering fast turnaround, high throughput, and enhanced safety. However, it mayfail to detect non-binding NAbs and has limited sensitivity,potentially resulting infalse-positive or false-negative results.
● PBNA:
PBNAs utilize replication-deficient pseudoviruses, offering a safer and more flexible option that can be performed in BSL-2 laboratories. These assaysenable high-throughput, automated workflows,employing reporter genes such as luciferase (Luc) or green fluorescent protein (GFP).Compatible with 96- and 384-well plate formats,PBNA resultscan be quantified using chemiluminescence readers or automated imaging systemslike Celigo. However, some discrepancies may existwhen compared with live virus assays.
|
Criteria |
Live Virus Neutralization Assay |
ELISA-Based Neutralization Assay |
PBNA |
|
Biosafety Requirements |
BSL-3 (forhigh-risk virus) |
BSL-1 |
BSL-2 |
|
Detection Time |
5-7 days |
1-2 hours |
1-2 days |
|
Throughput |
Low |
Medium |
High |
|
Functional Assessment |
Complete infection cycle |
Antigen binding only |
Invasion phase only |
|
Sensitivity |
High (Gold Standard) |
Medium to Low |
High (comparable to live virus) |
According to the World Health Organization (WHO) guidelines for vaccine production and control, PBNA is recommended for evaluating the efficacy of vaccines against human papillomavirus (HPV), rabies virus (RV), enterovirus 71 (EV71), human immunodeficiency virus (HIV), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), and others.
Pseudoviruses are recombinant viral particles that accomplish only a single round of infection. For non-enveloped viruses, pseudoviruses are typically produced using their own structural proteins. For enveloped viruses, packaging systemsbased on vesicular stomatitis virus (VSV) or HIV are used to generate pseudoviruses.
Genevoyager has established acomprehensive system forpseudovirus production and analytical method development,fully aligned with theGuidelines for Pseudovirus-Based Neutralization Assay. We offer PBNA services tosupport vaccine development and epidemiologicalresearch.
Schematic of Lentivirus-Based Pseudovirus Production and Neutralization Assay(Image source: Fantoni, Tobia et al., Journal of visualized experiments., 2023)
1. High authenticity:
Our pseudoviruses are designed toreplicate the viral envelope/capsid structure, offering ahighly accuratemodel of infection mechanismsobserved in clinical samples
2. Enhanced safety:
Engineered for single-round infection without the ability to self-replicate, the pseudovirusesofferhigh biosafety profile and can be safely handled in BSL-2laboratories
3. Superior stability:
An optimized production process guarantees consistent, high-qualitypseudovirus preparations across batches
4. Premium pseudovirus production performance:
Utilizing high-performance cell lines, we enable rapid production of highly active pseudoviruses
5. Clear, reliable results:
Multiple reporter gene systemssupport various preparationplatforms, with results easily readby chemiluminescence readers orCeligo imaging systems
1. Vaccine efficacy assessment:
Quantification of NAb levels in post-vaccination serum to assess immune protection
2. Drug screening and evaluation:
Identification and efficacy assessment of viral inhibitors
3. Infection mechanism research:
Investigation of viral entry and infection pathway
|
Cat. No |
Category |
Product Name |
Transgene |
Packaging Size |
Recommended Use |
|
PSNAb-0001 |
HPV-VLP |
PS-HPV(6)-VLP-L1＆L2-Luc |
L1＆L2, Luciferase |
100μL/vial |
Receptor-based drug screening, neutralizing antibody activity detection, vaccine efficacy evaluation |
|
PSNAb-0002 |
PS-HPV(11)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0003 |
PS-HPV(16)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0004 |
PS-HPV(18)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0005 |
PS-HPV(31)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0006 |
PS-HPV(33)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0007 |
PS-HPV(45)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0008 |
PS-HPV(52)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0009 |
PS-HPV(58)-VLP-L1＆L2-Luc |
||||
|
PSNAb-0010 |
RV-VSV Pseudovirus |
PS-Rabies virus -VSV-G -Luc＆GFP |
G, Luciferase+GFP |
100μL/vial |
|
|
PSNAb-0011 |
RV-LV Pseudovirus |
PS-Rabies virus -LV-G -Luc＆GFP |
G, Luciferase+GFP |
100μL/vial |
|
|
PSNAb-0012 |
MERS-VSV Pseudovirus |
PS-MERS-COV - VSV-S -Luc＆GFP |
S, Luciferase+GFP |
100μL/vial |
|
|
PSNAb-0013 |
MERS-LV Pseudovirus |
PS-MERS-COV -LV-S -Luc＆GFP |
S, Luciferase+GFP |
100μL/vial |
|
|
PSNAb-0014 |
Influenza-VSV Pseudovirus |
PS-Influenza-H1N1- VSV -HA＆NA-Luc |
HA＆NA, Luciferase |
100μL/vial |
|
|
PSNAb-0015 |
PS-Influenza-H3N2- VSV -HA＆NA-Luc |
||||
|
PSNAb-0016 |
PS-Influenza-H5N1- VSV -HA＆NA-Luc |
||||
|
PSNAb-0017 |
PS-Influenza-H7N9- VSV -HA＆NA-Luc |
||||
|
PSNAb-0018 |
Influenza-LV Pseudovirus |
PS-Influenza-H1N1- LV -HA＆NA-Luc |
HA＆NA, Luciferase |
100μL/vial |
|
|
PSNAb-0019 |
PS-Influenza-H3N2- LV -HA＆NA-Luc |
||||
|
PSNAb-0020 |
PS-Influenza-H5N1- LV -HA＆NA-Luc |
||||
|
PSNAb-0021 |
PS-Influenza-H7N9- LV -HA＆NA-Luc |
||||
|
PSNAb-0022 |
AAV-AAV Pseudovirus |
PS-Adeno-associated virus 2-AAV-VP-Luc |
AAV2-VP, Luciferase |
100μL/vial |
|
|
PSNAb-0023 |
PS-Adeno-associated virus 5-AAV-VP-Luc |
AAV5-VP, Luciferase |
|||
|
PSNAb-0024 |
PS-Adeno-associated virus 8-AAV-VP-Luc |
AAV8-VP, Luciferase |
|||
|
PSNAb-0025 |
PS-Adeno-associated virus 9 -AAV-VP-Luc |
AAV9-VP, Luciferase |
|||
|
PSNAb-0026 |
EBOV-VSV Pseudovirus |
PS-EBOV-VSV-GP-Luc |
GP, Luciferase |
100μL/vial |
|
|
PSNAb-0027 |
EBOV-LV Pseudovirus |
PS-EBOV-LV-GP-Luc |
GP, Luciferase |
100μL/vial |
● We offer ready-to-use SARS-CoV-2 pseudovirus vectors (VSV/LV-S), including wild-type and Omicron variants.
● Custom pseudovirus production services are available for a wide range of variants and reporter gene systems. Our pseudovirus assays demonstrate a high correlation with live virus neutralization results (>90%).
US: 3675 Market Street, Suite 200, Philadelphia, PA19104 Tel: +1 (215) 205-6963 | +086 027-65023363
E-mail: hui.wang@genevoyager.com
China: No128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China Tel: 17720522078
E-mail: marketing@genevoyager.com
US: 3675 Market Street, Suite 200, Philadelphia, PA19104 Tel: +1 (215) 205-6963 | +086 027-65023363
E-mail: hui.wang@genevoyager.com
China: No128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China Tel: 17720522078
E-mail: marketing@genevoyager.com
